



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

Date: 14.02.2022

To,
The General Manager,
Listing Department,
Bombay Stock Exchange
1st Floor, New trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai-400001

Dear Sir/Madam,

Sub: Financial Results for quarter ended 31.12.2021-Regulation 33

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting through Video Conferencing held on Monday, 14th February, 2022 at 11:00 A.M, interalia considered and approved the unaudited Financial Results for the quarter ended 31st December, 2021

Copy of Unaudited Financial Results for the quarter ended 31.12.2021 is enclosed herewith

Kindly take the same on record and acknowledge the receipt of same.

Thanking You
For Godavari Drugs Limited

Rashmi Agarwal
Company Secretary & Compliance Officer



V.SRIDHAR & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on unaudited quarterly financial results of Godavari Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To,
The Board of Directors
Godavari Drugs Limited

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and nine months ended December 31, 2021 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V Sridhar & Co.,
Chartered Accountants
FRN: 006206S


Venulapati Sridhar
Proprietor

ICAI Membership No. 202337
Hyderabad. February 14, 2022.
UDIN: 22202337ABYNMX9457.



GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECMEBER 31, 2021

(Rs. In Lakhs)

Sl. No	Particulars	Quarter ended			Nine months ended on		Year ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	3375.74	3866.67	3309.92	11682.59	8971.17	12267.01
2	Other Income	5.30	9.05	8.18	16.05	29.61	41.01
3	Total Revenue from operations (1+2)	3381.04	3875.72	3318.10	11698.64	9000.78	12308.02
4	Expenses						
(a)	Cost of materials consumed	2047.23	3290.26	2111.80	9000.59	6985.57	9414.80
(b)	Changes in inventories of finished goods & work-in-progress	639.74	-197.50	550.48	354.49	141.47	244.02
(c)	Employee benefits expense	130.56	132.29	107.81	380.99	275.16	394.31
(d)	Depreciation & amortization expense	43.37	42.53	28.80	127.65	84.78	122.27
(e)	Finance Costs	73.30	78.52	81.70	223.08	249.75	330.80
(f)	Other Expenses	299.69	351.26	282.94	1088.02	842.95	1231.18
	Total expenses	3233.90	3697.36	3163.53	11174.83	8579.68	11737.38
5	Profit before exceptional Items and tax (3-4)	147.14	178.36	154.57	523.81	421.10	570.64
6	Exceptional items						
7	Profit before Tax (5-6)	147.14	178.36	154.57	523.81	421.10	570.64
8	Tax expense	-13.92	-56.23	-54.31	-126.03	-136.93	-157.83
	Total Tax Expenses						
9	Net Profit for the period (7-8)	133.22	122.13	100.26	397.78	284.17	412.81
10	Other Comprehensive Income						
(i)	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii)	Income tax relating to Items that will not be reclassified to profit or loss						
(iii)	Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv)	Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-	-
11	Total Comprehensive Income (9+10)	133.22	122.13	100.26	397.78	284.17	412.81
12	Paid-up equity share capital	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity						1685.56
14	Earnings per share						
(a)	Basic	1.77	1.62	1.33	5.28	3.77	5.48
(b)	Diluted	1.77	1.62	1.33	5.28	3.77	5.48

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 14th February, 2022.
- The above results were prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Limited Review by the Statutory Auditors for the quarter as required under regulation 33(3)(c) of the Listing Agreement has been received.
- The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016, Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the company has opted to publish quarterly unaudited results at the quarter end.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

K.K.Jain
Director Finance
DIN: 00076657



Place: Secunderabad
Date: 14.02.2022